Pharmacological Management of Germinal Matrix-Intraventricular Hemorrhage

Germinal matrix-intraventricular hemorrhage (GM-IVH) is among the devastating neurological complications with mortality and neurodevelopmental disability rates ranging from 14.7% to 44.7% in preterm infants. The medical techniques have improved throughout the years, as the morbidity-free survival ra...

Full description

Saved in:
Bibliographic Details
Published inJournal of Korean Neurosurgical Society Vol. 66; no. 3; pp. 258 - 262
Main Authors Jaewoo Chung, Sang Koo Lee, Chun-Sung Cho, Young Jin Kim, Jung Ho Ko, Jung-Ho Yun, Jin-Shup So, In-Ho Jung
Format Journal Article
LanguageKorean
Published 2023
Subjects
Cerebral intraventricular hemorrhage
Preterm infant
Erythropoietin
Germinal matrix hemorrhage
Online AccessGet full text

Cover

More Information
Summary:Germinal matrix-intraventricular hemorrhage (GM-IVH) is among the devastating neurological complications with mortality and neurodevelopmental disability rates ranging from 14.7% to 44.7% in preterm infants. The medical techniques have improved throughout the years, as the morbidity-free survival rate of very-low-birth-weight infants has increased; however, the neonatal and long-term morbidity rates have not significantly improved. To this date, there is no strong evidence on pharmacological management on GM-IVH, due to the limitation of well-designed randomized controlled studies. However, recombinant human erythropoietin administration in preterm infants seems to be the only effective pharmacological management in limited situations. Hence, further high-quality collaborative research studies are warranted in the future to ensure better outcomes among preterm infants with GM-IVH.
Bibliography:KISTI1.1003/JNL.JAKO202317854648861
ISSN:2005-3711
1598-7876